FDA Renews Canalevia-CA1 for Chemotherapy Induced Diarrhea in Dogs Through 2026
Chemotherapy can be life saving for canine cancer patients, but anyone who has managed a dog with chemotherapy induced diarrhea knows how quickly GI side effects can derail treatment plans, stress pet parents, and drain clinic morale. That is why Jaguar Health’s latest news is worth your attention. The FDA has officially renewed the conditional approval of Canalevia-CA1, extending access to this targeted therapy for chemotherapy induced diarrhea in dogs through December 21, 2026.
Palliative Chemotherapy Shows Promise for Feline Carcinoma of Unknown Primary
Carcinoma of unknown primary, or CUP, is one of those diagnoses that makes even seasoned veterinary professionals pause. Despite advanced imaging, histopathology, and immunohistochemistry, the original tumor site remains elusive. In human oncology, CUP is relatively common and notoriously challenging, accounting for a notable percentage of new cancer diagnoses and carrying a guarded prognosis. In veterinary medicine, especially in cats, documented cases are few, leaving clinicians with limited guidance and a lot of tough conversations.
Altered microRNA Profiles and Associated Pathways in Canine Mammary Adenocarcinoma
Canine mammary tumors remain one of the most common neoplastic diagnoses in intact female dogs, and they continue to challenge clinicians with their biological diversity and unpredictable behavior. Among these tumors, mammary gland adenocarcinoma stands out for its aggressive nature and clinical relevance. Beyond their impact on canine health, these tumors also offer a powerful comparative model for human breast cancer. A recent study exploring microRNA expression in canine mammary adenocarcinoma adds a fresh molecular layer to this conversation and it is surprisingly relatable to what we already know from human oncology.
Does Histology Really Predict the Fate of Dogs With Osteosarcoma? The Answer Might Surprise You
Appendicular osteosarcoma remains one of the most emotionally and clinically challenging diagnoses in small animal oncology. It is aggressive, common, and often unforgiving, even when treated promptly. For veterinary professionals, the quest for reliable prognostic markers is constant. We want tools that help us guide treatment decisions, manage client expectations, and ideally improve outcomes.
Tiny Molecules, Big Trouble: How microRNAs Are Rewriting the Story of Canine Mammary Cancer
Canine mammary tumors are one of those diagnoses every small animal clinician knows too well. They are common, complex, and emotionally heavy for clients. Among them, mammary adenocarcinoma stands out as both prevalent and aggressive, making it a priority for better diagnostics and smarter therapies. Recent research into microRNA profiles is opening a new chapter in how we understand and potentially manage these tumors.
Cats Have Way More GI Tumors Than Dogs? What a National Cancer Database Just Revealed
Gastrointestinal disease is one of the most common reasons pets present to veterinary clinics. Vomiting, diarrhea, weight loss, and anemia are everyday complaints, yet behind these familiar signs can be some of the most challenging cancers we diagnose. A new comparative epidemiological study from Portugal sheds light on how tumors of the digestive system differ between dogs and cats, and the results reinforce something clinicians already sense in practice. These species are not playing the same oncologic game.